Change in Director Details

Smith & Nephew Plc

23 February 2024

 

23 February 2024

SMITH & NEPHEW PLC

Notification under Listing Rule 9.6.14

Anne-Francoise Nesmes, Chief Financial Officer of Smith & Nephew plc, will join the Board of Sanofi S.A. as an independent non-executive director with effect from 30 April 2024, subject to Sanofi shareholder approval.

 Enquiries

Investors Andrew Swift Katherine Rycroft Smith+Nephew	[phone] [phone]
Media Charles Reynolds Smith+Nephew	[phone]
Susan Gilchrist / Ayesha Bharmal Brunswick	[phone]

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 19,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

END